539730 FREDUN

Fredun Pharmaceuticals Share Price

 

 

Start SIP in FREDUN

Start SIP

Performance

  • Low
  • ₹1,855
  • High
  • ₹1,949
  • 52 Week Low
  • ₹635
  • 52 Week High
  • ₹1,999
  • Open Price₹1,907
  • Previous Close₹1,907
  • Volume3,148

Investment Returns

  • Over 1 Month + 21.04%
  • Over 3 Month + 44.73%
  • Over 6 Month + 157.1%
  • Over 1 Year + 143.41%

Smart Investing Starts Here Start SIP with Fredun Pharmaceuticals for Steady Growth!

Invest Now

Fredun Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 30.6
  • PEG Ratio
  • 0.5
  • Market Cap Cr
  • 885
  • P/B Ratio
  • Average True Range
  • 93.08
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 91.25
  • RSI
  • 58.65
  • MFI
  • 65

Fredun Pharmaceuticals Financials

Fredun Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,874.10
-32.95 (-1.73%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹1,830.86
  • 50 Day
  • ₹1,655.25
  • 100 Day
  • ₹1,434.62
  • 200 Day
  • ₹1,197.40

Resistance and Support

1892.63 Pivot Speed
  • R3 2,024.07
  • R2 1,986.43
  • R1 1,930.27
  • S1 1,836.47
  • S2 1,798.83
  • S3 1,742.67

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Fredun Pharmaceuticals has an operating revenue of Rs. 428.43 Cr. on a trailing 12-month basis. An annual revenue growth of 31% is outstanding, Pre-tax margin of 6% is okay, ROE of 14% is good. The company has a reasonable debt to equity of 7%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 17% and 83% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 98 which is a GREAT score indicating consistency in earnings, a RS Rating of 97 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 66 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of A is the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Fredun Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-08 Quarterly Results
2025-09-25 Preferential Issue of shares & Others To consider 1. Issue Of Warrants. alia, to consider a proposal for fund raising up to Rs.120 crores by way of further public offer, rights issue, debt issue, preferential issue or any other method.
2025-07-30 Quarterly Results
2025-05-30 Audited Results & Dividend
2025-02-04 Quarterly Results
Date Purpose Remarks
2025-09-23 FINAL Rs.0.70 per share(7%)Dividend
2024-09-23 FINAL Rs.0.70 per share(7%)Final Dividend
2023-09-22 FINAL Rs.0.70 per share(7%)Final Dividend
2022-09-15 FINAL Rs.0.70 per share(7%)Final Dividend
View Fredun Pharmaceuticals Dividend History Arrow

Fredun Pharmaceuticals F&O

Fredun Pharmaceuticals Shareholding Pattern

48.93%
0.01%
1.59%
43.74%
5.73%

About Fredun Pharmaceuticals

  • NSE Symbol
  • FREDUN
  • BSE Symbol
  • 539730
  • Managing Director & CFO
  • Mr. Fredun Medhora
  • ISIN
  • INE194R01017

Similar Stocks to Fredun Pharmaceuticals

Fredun Pharmaceuticals FAQs

Fredun Pharmaceuticals share price is ₹1,874 As on 08 December, 2025 | 02:50

The Market Cap of Fredun Pharmaceuticals is ₹884.9 Cr As on 08 December, 2025 | 02:50

The P/E ratio of Fredun Pharmaceuticals is 30.6 As on 08 December, 2025 | 02:50

The PB ratio of Fredun Pharmaceuticals is 6.8 As on 08 December, 2025 | 02:50

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23